Par Pharmaceutical announced the launch of Dexmethylphenidate Hydrochloride Extended-Release (ER) Capsules, the generic version of NovartisFocalin XR.

RELATED: Psychiatric Disorders Resource Center

Dexmethylphenidate HCl is a CNS stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD). Dexmethylphenidate, the more pharmacologically active d-enantiomer of racemic methylphenidate, is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

Dexmethylphenidate HCl is available in 15mg and 30mg ER capsules. Par has begun shipment of this product.

For more information call (800) 828-9393 or visit